All In Biotech

Drug Trial Radar · NCT05094336

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

329

Actual

Start

Feb 1, 2022

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Oct 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of Anvumetostat alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of Anvumetostat in adult participants with metastatic or locally advanced MTAP-null solid tumors.

Conditions

  • Advanced MTAP-null Solid Tumors

Interventions

  • AnvumetostatDrug

    Anvumetostat: Orally via tablet

  • DocetaxelDrug

    Docetaxel: Intravenous infusion

  • Comparator Anvumetostat Test TabletDrug

    Comparator Anvumetostat test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: Anvumetostat Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator Anvumetostat test tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1 and 2: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)Time frame: 28 days
  2. Parts 1 and 2: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)Time frame: Up to approximately 3 years
  3. Part 3: Objective Response Rate (ORR)Time frame: Up to approximately 3 years

Locations

75 sites in 14 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • California Research Institute

    Glendale, California

  • Fomat Medical Research

    Oxnard, California

  • University of California at SF

    San Francisco, California

  • D and H Cancer Research Center

    Margate, Florida

  • Boca Raton Clinical Research Medical Center Inc

    Tamarac, Florida

  • Goshen Health Systems

    Goshen, Indiana

  • Indiana University

    Indianapolis, Indiana

  • Community Health Network MD Anderson Cancer Center - North

    Indianapolis, Indiana

  • University of Maryland Medical Center

    Baltimore, Maryland

  • American Oncology Partners, PA

    Bethesda, Maryland

  • Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion)

    Detroit, Michigan

  • Washington University

    St Louis, Missouri

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Northwell Health Monter Cancer Center

    Lake Success, New York

  • New York University Grossman School of Medicine and New York University Langone Hospitals

    New York, New York

  • Duke University

    Durham, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Sanford Oncology Clinic and Pharmacy

    Sioux Falls, South Dakota

  • Sarah Cannon Research Institute

    Dallas, Texas

  • Center for Oncology and Blood Disorders

    Houston, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Lumi Research

    Kingwood, Texas

  • South Texas Accelerated Research Therapeutics

    San Antonio, Texas

  • University of Virginia Cancer Center

    Charlottesville, Virginia

  • Virginia Cancer Specialists PC

    Fairfax, Virginia

  • Chris OBrien Lifehouse

    Camperdown, New South Wales, Australia

  • Epworth Healthcare

    East Melbourne, Victoria, Australia

  • Peter MacCallum Cancer Centre

    Parkville, Victoria, Australia

  • Medizinische Universitaet Graz

    Graz, Austria

  • Landeskrankenhaus Salzburg

    Salzburg, Austria

  • Universite Catholique de Louvain Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Jessa Ziekenhuis - Campus Virga Jesse

    Hasselt, Belgium

  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg

    Leuven, Belgium

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.